Sunshine Biopharma, Inc. — FY 2011 Form 10-K
Business context and reporting period
Annual report for the fiscal year ended December 31, 2011. Sunshine Biopharma is a development-stage pharmaceutical company focused on cancer therapies. Its lead candidate, Adva-27a, completed early preclinical studies in 2011; the company had not begun clinical trials or generated revenue.
Financial condition and results
| Metric | FY 2011 / Dec. 31, 2011 | FY 2010 / Dec. 31, 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Total expenses and net loss | $556,202 | $537,382 |
| Loss per share | $0.02 | $0.02 |
| Cash used in operating activities | $297,299 | $348,325 |
| Cash from financing activities | $195,600 | $398,600 |
| Cash and cash equivalents | $60,692 | $162,391 |
| Total assets | $106,437 | $207,624 |
| Total liabilities | $3,434 | $11,404 |
Operating margins are not meaningful because the company had no revenue. The balance sheet reports no debt and only $3,434 of accounts payable. Current assets less current liabilities imply working capital of $103,003. The auditor’s report includes a going-concern paragraph, citing substantial doubt about the company’s ability to continue operating.
Material changes versus 2010
- Net loss increased by $18,820. FY 2011 included $142,650 of R&D expense, while public-relations expense rose to $140,504 from $60,366; license fees declined to $200,000 from $250,000 and consulting fees to $15,000 from $145,302.
- Operating cash use declined, but year-end cash fell by $101,699 to $60,692.
- Advanomics converted 850,000 preferred shares into 17 million common shares in December 2011. Common shares outstanding rose from 30.69 million to 48.73 million.
- A December 2011 license amendment replaced a previously stated $9.7 million obligation to purchase Advanomics shares with an annual $360,000 license fee plus reimbursement of Advanomics’ related R&D expenses. Advanomics is controlled by the company’s CEO.
Outlook, risks and unusual items
- The company estimated it would need approximately $5 million in debt and/or equity funding to implement its business plan. It reported no committed funding and warned that it might not secure sufficient capital; additional equity could materially dilute shareholders.
- Management expected Phase I trials for multidrug-resistant breast cancer in 2013, subject to financing, and anticipated trial completion by late 2014. These are forward-looking plans, not assured milestones. The company had made no regulatory filings and had no approved products.
- Key risks include going-concern uncertainty, ongoing losses and cash burn, clinical and regulatory failure or delay, manufacturing and commercialization challenges, competition, and dependence on a single product candidate and key personnel.
- Adva-27a’s reported activity and other favorable characteristics are based on preclinical work and may not predict human safety or efficacy. The company also said compassionate-use or fast-track pathways might be available, but provided no assurance.
- The independent auditor issued an unqualified opinion on the financial statements while emphasizing substantial doubt about continued operations. Management said disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether the company obtained enough financing to fund operations, the amended license payments, and planned clinical development.
- The current status and terms of the related-party license, including the $360,000 annual fee and reimbursement obligations.
- Whether Adva-27a advanced into IND-enabling work, regulatory review, or human trials, and whether timelines changed.
- Share-count changes, potential further dilution, and the effect of the 17 million-share preferred conversion.
- The filing states in its going-concern note that the company had a working-capital deficit, but the reported year-end balance sheet shows current assets exceeding current liabilities by $103,003; investors should clarify this inconsistency.